This company listing is no longer active
PHAXIAM Therapeutics (PHXM) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
PHXM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
PHAXIAM Therapeutics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.10 |
| 52 Week High | €2.15 |
| 52 Week Low | €0.027 |
| Beta | 1.74 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -93.95% |
| 3 Year Change | -98.58% |
| 5 Year Change | -99.80% |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHXM | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0% | 4.2% | -0.7% |
| 1Y | -93.9% | 362.6% | 0.7% |
Return vs Industry: PHXM underperformed the French Biotechs industry which returned 1.5% over the past year.
Return vs Market: PHXM underperformed the French Market which returned 4% over the past year.
Price Volatility
| PHXM volatility | |
|---|---|
| PHXM Average Weekly Movement | 0% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in FR Market | 10.9% |
| 10% least volatile stocks in FR Market | 2.5% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine PHXM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 68 | Thibaut Fayet | www.phaxiam.com |
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.coli), Pseudomonas aeruginosa (P.aeruginosa), and Staphylococcus aureus (S.aureus).
PHAXIAM Therapeutics S.A. Fundamentals Summary
| PHXM fundamental statistics | |
|---|---|
| Market cap | €1.01m |
| Earnings (TTM) | -€21.92m |
| Revenue (TTM) | €2.14m |
Is PHXM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHXM income statement (TTM) | |
|---|---|
| Revenue | €2.14m |
| Cost of Revenue | €0 |
| Gross Profit | €2.14m |
| Other Expenses | €24.06m |
| Earnings | -€21.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Sep 24, 2025
| Earnings per share (EPS) | -2.18 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,023.91% |
| Debt/Equity Ratio | 51.8% |
How did PHXM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/17 22:48 |
| End of Day Share Price | 2025/09/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PHAXIAM Therapeutics S.A. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael King | Citizens JMP Securities, LLC |
| Guillaume Cuvillier | Gilbert Dupont |
| Philippa Gardner | Jefferies LLC |